Pill with imprint GSI is Pink, Capsule/Oblong and has been identified as Complera emtricitabine 200 mg, rilpivirine 25 mg and tenofovir disoproxil fumarate 300 mg. It is supplied by Gilead Sciences, Inc. Complera is used in the treatment of HIV Infection and belongs to the drug class antiviral combinations.

2024年6月19日 · Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is used to treat human immunodeficiency virus (HIV). Learn more about How Biktarvy Works for HIV Infection. Biktarvy may also be used for...

Pill Identifier results for "GSI". Search by imprint, shape, color or drug name.

Pill with imprint GSI 9883 is Brown, Capsule/Oblong and has been identified as Biktarvy bictegravir 50 mg / emtricitabine 200 mg / tenofovir alafenamide 25 mg. It is supplied by Gilead Sciences, Inc. Biktarvy is used in the treatment of HIV Infection and belongs to the drug class antiviral combinations.

This blue rectangle pill with imprint GSI 225 on it has been identified as: Descovy 200 mg / 25 mg. This medicine is known as Descovy (generic name: emtricitabine/tenofovir alafenamide). It is …

2025年2月24日 · ODEFSEY is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 25 kg: as initial therapy in those with no antiretroviral ...

2024年8月10日 · Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is used to treat human immunodeficiency virus (HIV). Genvoya may also be used for other conditions as determined by your...

Pill with imprint GSI 225 is Blue, Rectangle and has been identified as Descovy 200 mg / 25 mg. It is supplied by Gilead Sciences, Inc. Descovy is used in the treatment of Pre-Exposure Prophylaxis; HIV Infection and belongs to the drug class antiviral combinations.

2024年6月23日 · What is Descovy used for? Descovy (emtricitabine/tenofovir alafenamide) is commonly used for the following conditions. Learn more about Descovy for HIV. Descovy may also be used for other...

2024年8月30日 · Biktarvy is a single pill that contains bictegravir (50 mg), emtricitabine (200 mg) and tenofovir alafenamide fumarate (25 mg). Biktarvy was approved by the FDA in the US in February 2018 and in June 2018 in Europe. Biktarvy is a 3-in-1 single combination pill that is taken once-daily. Biktarvy can be taken with or without food.